GLP-1 market heats up as companies vie for next-gen obesity drugs
Oct 31, 2024 · Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their …
$680M deal with CBC and Mubadala shifts UCB's strategy
Aug 29, 2024 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's …
Novocure's TTFields therapy boosts survival in pancreatic cancer
Dec 3, 2024 · Swiss oncology specialist Novocure has announced positive topline results from the PANOVA-3 phase 3 clinical trial, which evaluated the use of tumor treating fields (TTFields) …
Interview: Adragos Pharma and the evolving world of outsourcing
Oct 4, 2024 · Outsourcing Pharma sat down ahead of CPHI with Dr Andreas Raabe, CEO of Adragos Pharma, to explore the evolving world of pharmaceutical outsourcing.
Archives 2025 - Outsourcing-Pharma.com
Jan 3, 2025 · News & Analysis on Clinical Trial Services & Contract Research And Development. Register. Search
Symbiosis unveils expanded facility at CPHI Milan 2024
Oct 2, 2024 · The event provides a great platform for the company to present its newest addition—a 20,000 sq ft facility in Stirling, UK, which the company says enhances Symbiosis' …
How will the Biosecure Act impact the pharma industry?
Oct 8, 2024 · But what does the Act mean for the biotech and pharma industry and how can companies best prepare for any impacts on future business? The Biosecure Act was first …
NorthStar launches radiopharmaceutical CDMO
Oct 24, 2024 · The increasing integration of medical radioisotopes with diagnostic and molecular imaging as well as the rise of personalized medicine is spurring the growth of the global …
uMotif acquires ClinOne, integrates eConsent for clinical trials
Sep 17, 2024 · uMotif CEO Steve Rosenberg. ClinOne’s integration brings added capabilities to uMotif’s platform, including improved consent management, enhanced site productivity, and a …
F2G raises $100M to advance olorofim after FDA rejection
Sep 17, 2024 · Founded in 1998, F2G raised $60.8 million in 2020 and $70 million in 2022 to finance its pipeline development. The company is also running programs for indications …